Akers Biosciences Share Discussion Threads

[norbus] 29/2/2016 07:36

mcm

finally your prayers are answered and we have a whole commercial team

[mcmather] 25/2/2016 00:07

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 14 December 2006; Akers Biosciences Inc. is pleased to announce that it has obtained a sales and marketing license from a US diagnostic products company for the development, marketing and distribution of five additional diagnostic tests. These tests are intended to broaden Akers' home diagnostic product line, both in the United States and Europe. The products that were licensed include tests for pregnancy, fertility (ovulation), urinary tract infection, kidney/bladder function, and diabetes in urine. These tests will be marketed under the Company's "Check" trademark. All of the licensed products are FDA-cleared, and will be introduced into the marketplace in January, 2007. The Company will seek product approval for these products in the European Union.

Dr. Ray Akers said, "The expansion of our home diagnostic product line represents (if you say it, you stink) a significant step (you stink) in our strategy to penetrate the home healthcare market. With established relationships in three major retail channels, these additional products provide critical mass that should accelerate sales across all of our home diagnostic products."

[mcmather] 25/2/2016 00:01

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 30 October 2006; Akers Biosciences Inc. is pleased to announce that it has signed an agreement with Pulse Marketing Corp. for the marketing and distribution of Akers' home cholesterol and free radical tests to direct sales companies, most of whom are members of the Direct Selling Association. The agreement includes development funds to be paid to Akers to modify the tests to Pulse's specifications, and then provides for manufacturing of the products by Akers for Pulse. Pulse, whose distribution reaches over 1 million independent business owners in North America alone, intends to market the products as soon as the development phase is completed, which is targeted for March 2007.

Dr. (yippee) Ray Akers said, "Today's agreement represents (guess what??) a significant step in our strategy to penetrate a large segment of the U.S. home healthcare market. There is a clear medical need for our breakthrough tests for cholesterol and free radicals, and this agreement fits nicely with the trends in wellness and health awareness among U.S. consumers. This alliance with Pulse Marketing will make our product more widely available to consumers across the U.S., and will significantly increase our share of voice in the marketplace."

[mcmather] 24/2/2016 23:53

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 11 October 2006; Akers Biosciences Inc is pleased to announce today that it has received market clearance from the National Highway Traffic Safety Administration of the United States Department of Transportation ("DOT") for its new Breath Alcohol Check .02 Detection System.

Following this approval, the company's products will be distributed by Quest Diagnostics, Inc. and the company's network of distributors. The Company believes that the DOT approval will positively impact the pursuit of sales in other market sectors, including law enforcement, employee screening, personal use, and the educational system.

Dr. (about chuffin time) Ray Akers said, "This is a significant milestone in the expansion of our breathalyzer business. We believe that this approval will produce revenues in 2006."

[mcmather] 24/2/2016 23:45

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 29 September 2006; The Company's flagship product, the PIFA Heparin/PF4 Rapid Assay, has been introduced to over 500 hospitals through the Company's distributors, supported by the Company's sales team.

Subject to the signing of a military contract for the breathalyzer product, second half trading is expected to significantly exceed that of period under review; is this simple speculation??

Ray Akers said: Why am I not referred to as a Dr yer b'stard? Nah, he didn't, but he did say "By combining forces with the leader in the alcohol breathalyzer business, WNCK Inc., we took yet another step in our long-range plan to lead and reshape this industry (I'm writing this nearly, ahem, a decade later!). We are also pleased to announce today the market introduction of our Breath Alcohol Check .02 Detection System. This product represents the next generation of our breathalyzer product line through the inclusion of an electronic detection device coupled with our disposable breathalyzers, thereby strengthening our product offering. We continue to build the market penetration of our other key tests for heparin/platelet factor-4 antibodies and Tri-Cholesterol, and expect a positive sales trend for the full year and beyond"...

[mcmather] 24/2/2016 23:31

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. Noting his ambition to grow the company (from numerous telephone conversations with him) what happened here Sepp which resulted in Thomas Nicolette leaving the company in 2014?

RNS 11 May 2006; Akers Biosciences, Inc., is pleased to announce the appointment of Thomas A. Nicolette as Non-Executive Director, effective immediately. Akers believes that Mr. Nicolette's background in sales, manufacturing and experience as Chief Executive Officer of several companies publicly listed in the U.S. will be of great benefit to the Company.

[mcmather] 24/2/2016 23:27

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 3 May 2006; Akers Biosciences Inc. is pleased to announce today that it has received market clearance from the U.S. Food and Drug Administration ("FDA") for its rapid alcohol breathalyzers. Four different
versions of the product were cleared, each detecting a specific amount of
breath alcohol.

Dr. Ray Akers said, "This is a significant milestone in the expansion of our breathalyzer business. We are ahead of the competition with respect to regulatory clearances, and this should have a positive impact on our market penetration."

[mcmather] 24/2/2016 23:22

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 4 April 2006; $7.75 million financings completed for expansion of production and sales force; have we seen this very same line quoted since by the good doctor?

Over 300 hospitals now using HPF-4 test; over 60 Lithium systems placed in psychiatrist's offices. Cardinal Health and Corgenix Laboratories have begun marketing of the HPF-4 test in the US; remember this was a DECADE ago - let's see how well sales have gone for this range of products in 2015.

Italian government approval Breathalyzer for enforcement of drunk driving laws could result in significant sales; hmmm, have we heard that one since??

Ray Akers said: "We are very pleased to report record-breaking revenues and expect revenues in 2006 to be even stronger. We have undertaken an ambitious program that we believe will result in an increase in the customer base of all products, expansion of our manufacturing capabilities, and the integration of a recent acquisition in the breathalyzer field. Revenues for 2006 will be shaped in large part by three core products: the home Tri-Cholesterol Check test, the PIFA Heparin/PF-4 Rapid Assay, and the Alcohol Breathalyzer (let's see what Walt says for the year ahead in 2016?!). The Company's outlook for 2006 is very positive and we expect another record-breaking year." And WE EXPECT ANOTHER RECORD BREKING YEAR - a legal comment to make?

[mcmather] 24/2/2016 23:10

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 3 April 2006; Akers Biosciences Inc. is pleased to announce that it has signed an agreement with McKesson Medical-Surgical Inc. to distribute Akers' PIFA� Heparin / Platelet Factor-4 Rapid Assay to hospital and laboratory customers in the US. The addition of McKesson will escalate the scale of personnel distributing the product and the regions in which Akers is able to penetrate.

Dr. Ray Akers said, "The broad reach of McKesson into the US healthcare marketplace provides us with another powerful route to distribute our flagship product (and remember this was a DECADE AGO!), the PIFA� Heparin / Platelet Factor-4 Rapid Assay. This alliance with McKesson is all about making our product even more widely available to hospitals across the U.S."

What reference will be made to the "flagship product" in the soon to be announced results for 2015? How much progressed will have been made here in the past DECADE? Who has overseen this 'progress' and who is responsible for its success and/or failure?? Any chance of a response here from Dr Raymond F. Akers Jr., Ph.D. or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences?

[mcmather] 24/2/2016 23:04

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 28 February 2006; Akers Biosciences, Inc. is pleased to announce that it has successfully completed the acquisition of the assets of WNCK, Inc. WNCK is the leading distributor of disposable alcohol breathalyzers in the U.S. Its Breath Scan product line has been one of the industry standards for the past 15 years. Akers has been the sole manufacturer of WNCK's products for the past 5 years.

Dr. Ray Akers said, "We are very pleased to add the highly established Breath Scan product line of WNCK to our Breath Alcohol Check line of alcohol breathalyzers. Together, Akers and WNCK will command a strong presence in the market place. We have been very successful at organically growing our own business, and welcome the opportunity to enhance this complementary product line."

[mcmather] 24/2/2016 22:58

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 13 February 2006; Chief Executive Officer Ray Akers said "We are very pleased to report record-breaking revenues for our Company in the fiscal year 2005, and expect revenues in 2006 to be even stronger. Momentum for our core products continues to build, and the company will expand the market for its products in 2006 through the strengthening of existing strategic alliances, and the development of new partnerships."

[mcmather] 24/2/2016 22:55

Open question to anyone and including Dr Raymond F. Akers Jr., Ph.D. but what did this really relate to?

RNS 13 February 2006; Following the adoption by the Company of U.S. GAAP treatment of options and warrants, it is expected that reported results for the period will be impacted by a non-tax charge estimated at $1.6 million. This reflects, to a large extent, the accounting impact of the warrants issued in conjunction with the debt facility with Platinum Partners which was announced on 14 March 2005.

[mcmather] 18/2/2016 15:19

Not sure what happened there but nasdaq now back down to $1.51 - between 13.71 to 20% dependent on which site you view.

Open question still applies from post #3055 onwards to Dr Raymond F. Akers Jr., Ph.D. to answer, or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences; what went wrong and who is to blame here?

[mcmather] 18/2/2016 00:10

Bizarrely, seemingly the top riser on nasdaq...

Most Actives % Gainers

Symbol Company Name Price Change % Change Volume 1-Day

AKER Akers Biosciences Inc. 1.75 +0.40 +29.63% 86,267
OCUL Ocular Therapeutix, Inc. 8.67 +2.41 +38.50% 5,616,151
IO ION Geophysical Corporation 3.96 +0.93 +30.69% 231,823
PLG Platinum Group Metals Ltd. 1.94 +0.44 +29.33% 2,098,406
FOSL Fossil Group, Inc. 44.30 +9.84 +28.55% 11,836,422
BUR Burcon Nutrascience Corporation 1.85 +0.37 +25.00% 146,374
GRN iPath Global Carbon ETN 6.37 +1.84 +40.62% 2,488
WG Willbros Group Inc. 1.48 +0.30 +25.42% 220,473
RRMS Rose Rock Midstream, L.P. 11.84 +2.36 +24.89% 988,726

[mcmather] 17/2/2016 23:59

BTW the close on nassdaq today appears to have been $1.89; which equates to £1.32. Not sure whether this is related to Uncle Walt spreading his love recently:

Akers Biosciences ‏@AkersBio · Feb 10
Chairman Ray Akers to present at Source Capital’s 2016 Disruptive Growth & Healthcare conference in #NewYork today

[mcmather] 17/2/2016 23:45

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 3 January 2006; only a decade of this shenanigans to go:
Dr. Walter Akers commented, "This expansion is directly in response to both current and anticipated future levels of demand for Akers Biosciences' products and, in particular, the PIFA Heparin/ Platelet Factor-4 Rapid Assay which is now being used in over 200 hospitals in the United States alone, and the Tri-Cholesterol Check Assay which will be in US retail stores in the first quarter of 2006. This move marks the transition towards high volume manufacturing - an exciting milestone in our development."

[mcmather] 17/2/2016 23:39

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 5 October 2005:
Akers Biosciences, Inc. is pleased to announce that it has received an initial $2.1million order for its Tri-Cholesterol Check rapid home cholesterol test panel from its key US retail partner, Alco Industries.

In addition, the Company is pleased to announce that the positive growth trend
in the placement of its PIFA Heparin/PF4 test has continued, with over 165
hospitals now using the product.

As a result of this activity, and the likelihood of increasing future orders
for these and other products, the Company is putting into action plans to increase its manufacturing capabilities and product inventories".

[mcmather] 17/2/2016 23:36

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 27 September 2005:
Second half trading expected to significantly exceed that of period under review.

Sales activities of the company's flagship product, the PIFA Heparin/PF4 rapid test, commenced by both the Company's direct sales force and Corgenix Medical Group.

The Company introduced its products in the UK and certain EU countries through new alliances with Helena Biosciences Europe and Advanced Rapid Diagnostics Ltd.

Ray Akers said: "The second quarter of the period saw a distinct uplift in sales due largely to our flagship PIFA Heparin/PH4 rapid test product. As of today, our test for heparin/PF-4 antibodies is being used in approximately 140 hospitals in the United States, and that number continues to grow by 5-10 hospitals each week. We gained further momentum through the receipt of other product approvals and the establishment of important distribution and business relationships, and have begun to translate this momentum into product sales. This is the first time in the Company's history that we have an established customer base and one that is rapidly expanding. In addition, we have begun to establish a presence in UK and European markets and are in our most attractive position to date."

[mcmather] 17/2/2016 23:19

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 26 July 2005:
The Board of Akers is pleased to update the market on recent developments: The Company is pleased to announce that the US FDA has indicated that the Company may market its Tri-Cholesterol test OTC to consumers in the US, making it the only OTC test on the market that can rapidly determine total, HDL, and LDL cholesterol levels.

The Company's PIFA Heparin/PF 4 antibody rapid test is now gaining acceptance in the US hospital laboratory market, with over 50 hospitals now using this test. The rate of product adoption among new hospitals indicates a significant growth trend.

As a result of this market acceptance, and the selling efforts of the Company's distributors and its own sales force, orders for the PIFA HPF4 test have significantly increased. Akers' production and supply departments are well positioned to fulfil this increased demand. The product is expected to be introduced into the EU before the end of the year, with revenues expected to begin in early 2006.

Through its distributors, the Company's breathalyzer has been approved by the Italian government for use by police and other law enforcement officials in a campaign to decrease the incidence of driving under the influence of alcohol.

[mcmather] 17/2/2016 23:04

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 28 April 2005:
Dr. Ray Akers said, "This CLIA waiver is key to the penetration of psychiatrists' office and other point of care markets in the US. Psychiatrists can now make clinical decisions at the time of treatment based on rapid test data, and patients can gain confidence that their treatment levels are therapeutic and safe. Just as instant glucose meters advanced the way physicians treat diabetes, the CLIA waived status of the InstaRead Lithium System marks the beginning of an age when psychiatrists too can use rapid diagnostic tools in their own practice of medicine." Honest, this is what he said in this RNS.